FGF13-AS1: FGF13-AS1 is a long noncoding RNA (lncRNA) that functions as a tumor suppressor in breast cancer (BC) by inhibiting cell proliferation, migration, and invasion, as well as impairing glycolysis and stemness properties [PMC8810037]. It achieves these effects by promoting the degradation of c-Myc mRNA through attenuating the interaction between IGF2BPs and c-Myc mRNA [PMC8810037]. The expression of FGF13-AS1 is decreased in BC tissue [PMC8810037]. It has been found that FGF13-AS1 suppresses cell glycolysis and stemness properties via the IGF2BPs/c-Myc pathway in BC [PMC7874641]. FGF13-AS1 destabilizes Myc mRNA through binding IGF2BPs and disrupting the interaction between Myc mRNA and IGF2BPs [PMC9022635]. Additionally, FGF13-AS1 inhibits proliferation, migration, and invasion of BC cells by inhibiting glycolysis and stem cell properties [PMC8732815]. FGF13-AS1 has been shown to have a feedback loop with Myc in regulating its suppressive effects in BC [PMC6896003]. It has been reported that many lncRNAs play important roles in tumor cell growth, metastasis, invasion, apoptosis, and metabolism [PMC7382762][PMC8806870]. In BC specifically, FGF13-AS1 acts as a tumor suppressor by impairing glycolysis and stemness properties through its interaction with IGF2BPs to reduce the half-life of Myc mRNA [PMC8404292][PMC8864352][PMC8348144][PMC7690038][PMC7510505]. Furthermore, reduced expression of FGF13-AS1 is associated with poor prognosis in BC [PMC9247199]. FGF13-AS1 has also been shown to inhibit glycolysis, OCT4 and SOX2 expression, spheroid formation, and maintenance of the CD44+CD24- population of BC cells [PMC9688207]. Overall, FGF13-AS1 is a lncRNA that acts as a tumor suppressor in BC by impairing glycolysis and stemness properties through its interaction with IGF2BPs and c-Myc mRNA [PMC9247199].